Repligen corp stock.
The United States Marines traces its roots back to 1776, and it’s the oldest military institution in the country. When Marines earn distinction during their service, the Marine Corps recognizes this service with a variety of medals and ribb...
7.05%. Trailing 12-Months. The Repligen Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.Repligen Corp’s ( RGEN) price is currently up 23.95% so far this month. During the month of July, Repligen Corp’s stock price has reached a high of $177.18 and a low of $134.64. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $134.64. Year to date, Repligen Corp’s stock is down 33.79%.CI. Repligen Insider Sold Shares Worth $557,328, According to a Recent SEC Filing. Nov. 13. MT. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07. MT. CORRECTION : RBC Trims Price Target on Regeneron Pharmaceuticals to $837 From $847, Keeps Sector Perform Rating. Nov. 03.Repligen Corp Stock Price History. Repligen Corp’s price is currently down 21.75% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $124.12. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $134.64. Year to date, Repligen Corp’s stock is ...In a report released today, Puneet Souda from SVB Securities maintained a Buy rating on Repligen (RGEN – Research Report), with a price target of $200.00.The company’s shares opened today at ...
Shares of bioprocessing technology company Repligen (RGEN 0.98%) were down by 10% on heavy volume as of 12:42 p.m. ET Tuesday. ... Why Repligen Corporation Stock Is Storming Higher Today.
CI. Repligen Insider Sold Shares Worth $557,328, According to a Recent SEC Filing. Nov. 13. MT. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07. MT. CORRECTION : RBC Trims Price Target on Regeneron Pharmaceuticals to $837 From $847, Keeps Sector Perform Rating. Nov. 03.
Repligen Corp. SEC filings breakout by MarketWatch. View the RGEN U.S. Securities and Exchange Commission reporting information.Information on stock, financials, earnings, subsidiaries, investors, and executives for Repligen. Use the PitchBook Platform to explore the full profile. ... Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies an. Biotechnology. Waltham, MA. 2,025 As of 2022 00000000. 000000.The share price of Repligen Corp. (NASDAQ:RGEN) dipped -2.38% to close Friday’s market session at $119.58, lower as compared to yesterday’s close. The stock price fluctuated between $118.08 and $122.45 throughout the trading session with the volume trading being 788849 shares, which represented a significant variation when …Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Analysts expect adjusted earnings to reach $1.752 per share for the current fiscal year. Repligen Corp does not currently pay a dividend. How We Compare Steris PLC and Repligen Corp Stock ...The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, …
Shares of the bioprocessing giant Repligen Corporation ( RGEN 4.89%) are glowing green today. Specifically, the biotech's stock was up by as much as 14.9% earlier today. Repligen's shares have ...
Promising Performance: Repligen Corp (RGEN) Stock Shows Potential for Strong Growth in 2023. On November 1, 2023, Repligen Corp (RGEN) stock had a promising performance based on the information provided. According to the data from CNN Money, the 13 analysts offering 12-month price forecasts for RGEN had a median target …
Repligen Corp Stock Price History. Repligen Corp’s price is currently down 21.75% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $124.12. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $134.64. Year to date, Repligen Corp’s stock is ...Oct 12, 2021 · The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last ... A high-level overview of Repligen Corporation (RGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.In 2022, Repligen's revenue was $801.54 million, an increase of 19.54% compared to the previous year's $670.53 million. Earnings were $185.96 million, an increase of 44.95%. Financial Statements.Repligen Corp (RGEN) Stock Shows Promising Performance on September 12, 2023: Analysts Predict 22.75% Increase. On September 12, 2023, Repligen Corp (RGEN) stock showed promising performances based on the information provided by CNN Money. The 13 analysts offering 12-month price forecasts for RGEN have a median …Find real-time RGEN - Repligen Corp stock quotes, company profile, news and forecasts from CNN Business. Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the ...
RGEN SEC Filings - Repligen Corp.- Annual Report, Proxy Statement, Prospectus ... DEFINITIONS The name of the plan is the Second Amended and Restated 2001 Repligen Corporation Stock Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and other. 2008-08-08:Oct 23, 2023 · Repligen Corp stock has a Value Score of 5, Growth Score of 82 and Momentum Score of 41. Comparing Premier Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. Avantor Inc does not currently pay a dividend. Currently, Repligen Corp’s price-earnings ratio is 63.2. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Analysts expect adjusted earnings to reach $1.748 per share for the current fiscal ...× Funding Description. Security: Description: Exchange: SYMBOL: Common stock, $0.01 par value: EXCHANGEReal-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock...
Repligen Corp stock has a Value Score of 4, Momentum Score of 73 and Quality Score of 72. Comparing Becton Dickinson and Co and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …Oct 12, 2021. The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop ...
Find the latest Repligen Corp (RGN.BE) stock quote, history, news and other vital information to help you with your stock trading and investing.Phone 1 781 250-0111. Industry Biotechnology. Sector Health Care/Life Sciences. Fiscal Year-end 12/2023. Revenue €801.54M. Net Income €185.96M. 2022 Sales Growth 19.54%. Employees 2,025.Nov 30, 2023 · The latest Repligen stock prices, stock quotes, news, and RGEN history to help you invest and trade smarter. A vertical stack of three evenly spaced horizontal lines. ... Repligen Corp. is a ... Find the latest Repligen Corporation (RGN.F) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Repligen Corporation (NASDAQ:RGEN) Q3 ...Repligen Corp. - RGEN STOCK NEWS . IMPACT. SENTIMENT. 11/14/2023 02:01 PM. RGEN: Nasdaq ... Repligen Corp. Nasdaq:RGEN. RGEN Rankings #1033 Ranked by Market Cap #4078 Ranked by Stock Gains. N/A Ranked by Dividends. RGEN Stock Data. Industry Biological Product (except Diagnostic) Manufacturing .Find the latest Repligen Corp (RGN.MU) stock quote, history, news and other vital information to help you with your stock trading and investing.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 12.34% in the past year. Currently, Repligen Corp’s price-earnings ratio is 74.0. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Mar 22, 2023 · Repligen Corp’s ( RGEN) price is currently down 4.66% so far this month. During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $160.14. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 37.23%. Inspire Medical Systems Inc. 151.72. +6.41. +4.41%. Get Repligen Corp (RGEN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.
The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last ...
Repligen Corporation Prices Public Offering of Shares of Common Stock. 6/27/2017. Summary. WALTHAM, Mass., June 27, 2017 (GLOBE NEWSWIRE) - Repligen Corporation ...
4 thg 4, 2016 ... Once you've won approval for a biologic, or biosimilar, manufactured at a particular facility, you can't just switch to another without jumping ...Item 2.02. Results of Operations and Financial Condition. On February 22, 2023, Repligen Corporation announced its financial results for the fourth quarter and year end December 31, 2022. The full...Apr 25, 2023 · Shares of bioprocessing technology company Repligen (RGEN 0.98%) were down by 10% on heavy volume as of 12:42 p.m. ET Tuesday. ... Why Repligen Corporation Stock Is Storming Higher Today. Get the latest Repligen Corporation (RGEN) stock news and headlines to help you in your trading and investing decisions. ... Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ ...Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 38 and Quality Score of 71. Comparing Abbott Laboratories and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …Dec 1, 2023 · See the latest Repligen Corp stock price (RGEN:XNAS), related news, valuation, dividends and more to help you make your investing decisions. 4.08%. $2.65B. CureVac N.V. 1.85%. $1.21B. RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. When starting a business, one of the most critical decisions you’ll have to make is choosing the right legal structure. Limited Liability Companies (LLCs) and S Corporations (S Corps) are two popular options for entrepreneurs, each with its...The stock of Repligen Corp. (NASDAQ: RGEN) has increased by 2.04 when compared to last closing price of 157.00. Despite this, the company has experienced a 2.74% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-07 that WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Repligen …
Repligen Corp (RGEN) Stock Shows Positive Performance and Promising Price Forecasts in the Biopharmaceutical Industry. On November 2, 2023, Repligen Corp (RGEN) experienced positive stock performance, with analysts forecasting a potential increase in its stock price. According to data from CNN Money, there are 13 analysts …45.74%. Dividend Yield. N/A. When it delivered its Q4 2022 report back in February, Repligen warned investors that in 2023, it expects a dip in revenue of between $1.5 million and $40 million due ...Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Instagram:https://instagram. interest only mortgage lendersautomated day trading softwaredell stock pricesluke lango net worth Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 38 and Quality Score of 71. Comparing Abbott Laboratories and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as … investing in assisted living facilitiesbest app to start investing in stocks Dec 1, 2023 · Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 35 and Quality Score of 70. Comparing Adapthealth Corp and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. The share price of Repligen Corp. (NASDAQ:RGEN) dipped -2.38% to close Friday’s market session at $119.58, lower as compared to yesterday’s close. The stock price fluctuated between $118.08 and $122.45 throughout the trading session with the volume trading being 788849 shares, which represented a significant variation when … national oil varco stock T&C apply*. Buy Repligen Corp Shares from India at $157.25 (0 Commission) today. Start investing in Repligen Corp stocks from India now with fractional investing only on INDmoneyapp.The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Repligen Corp. shares valued at $557,328 were sold by Gebski Christine on Nov 10. At $147.13 per share, Gebski Christine sold 3,788 shares.Repligen Corp ( RGEN) receives a weak valuation ranking of 32 from InvestorsObserver data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. RGEN has a better value than 32% of stocks based on these valuation analytics.